CSF2 and neoplasm: The therapeutic efficacy of the ESC/GM-CSF combination vaccine was associated with robust tumor-specific primary and long-term memory CD8+ T effector responses, infiltration of CD8+ T cells into the tumor leading to increased intratumoral CD8+ T effector/T regulatory cell ratio and reduced myeloid derived suppressor cells (MDSCs) in the spleen.